Silver A J, Flood J F, Song A M, Morley J E
Geriatric Research, Education, and Clinical Center, Sepulveda Veterans Administration Medical Center 91343.
Am J Physiol. 1989 Mar;256(3 Pt 2):R646-52. doi: 10.1152/ajpregu.1989.256.3.R646.
The effects of L-364,718, a cholecystokinin receptor antagonist, on cholecystokinin octapeptide-induced inhibition of food, and its effect on food intake when given alone, were studied in mice using several different feeding paradigms. In all studies, L-364,718 (100 micrograms/kg, 1.0 mg/kg) reversed the ability of cholecystokinin octapeptide to decrease food intake. L-364,718 enhanced food consumption compared with controls in nonfasted mice (100 microgram/kg) and in prefed mice (50, 100, 250 micrograms/kg). The number of reinforcements, using a lever press, was also enhanced by L-364,718 (100 micrograms/kg) compared with control. In other paradigms, L-364,718 failed to enhance food intake. These results are compatible with the suggestion that cholecystokinin may play a physiological role in the regulation of food intake.
在小鼠中,使用几种不同的进食模式,研究了胆囊收缩素受体拮抗剂L-364,718对胆囊收缩素八肽诱导的进食抑制的影响,以及单独给药时对食物摄入量的影响。在所有研究中,L-364,718(100微克/千克、1.0毫克/千克)逆转了胆囊收缩素八肽减少食物摄入量的能力。与未禁食小鼠(100微克/千克)和预喂小鼠(50、100、250微克/千克)中的对照组相比,L-364,718增加了食物消耗量。与对照组相比,L-364,718(100微克/千克)通过杠杆按压增加的强化次数也更多。在其他模式中,L-364,718未能增加食物摄入量。这些结果与胆囊收缩素可能在食物摄入调节中发挥生理作用的观点一致。